Press releases – NanoPhoria bioscience

6 October 2025

NanoPhoria Bioscience secures €83.5 Million Series A to Advance Breakthrough Heart Failure Therapy and Expand Portfolio for Novel Nano-in-Micro Delivery Platform

26 February 2025

NanoPhoria Bioscience Awarded €17.5 M From European Innovation Council’s Accelerator Program

8 January 2024

NanoPhoria appoints Dr Suman Shirodkar as chair and Prof. Michael Davidson as non-executive member of the Board of Directors

2 January 2024

NanoPhoria Bioscience publishes groundbreaking study in major cardiology journal

5 November 2022

Alessio Alogna, one of the founders of NanoPhoria, presented our inhalation-based approach to treat HFrEF in a large animal model at the American Heart Association’s annual Scientific Sessions event, which was held this year in Chicago (AHA 2022)

1 June 2022

NanoPhoria is on LinkedIn

22 May 2022

NanoPhoria receives a 3.5M€ seed grant from Sofinnova Partners a leading European life sciences venture capital firm based in Paris, London and Milan

16 May 2022

NanoPhoria has been granted an exclusive patent licence for a drug delivery platform based on inorganic nanoparticles. This acquisition will aid in the launch new products capable of optimizing the results of therapies and reducing side effects for patients